The research program “NextGen LOGGIC: Next-generation therapies for low-grade glioma in children” aims at the improvement of therapy of children with the most common benign brain tumors, pediatric low-grade glioma (pLGG). Preclinical data is generated in collaboration with the global LOGGIC pLGG phase III trial that will form the basis for next-generation clinical trials, such as LOGGIC EPILOGUE. Signaling pathways, the proteome and the response to novel drugs in pLGG models and primary tumors were investigated.
We have validated drug combinations as novel therapies for the treatment of pLGG, comprising MAPK inhibitors and senolytic agents. Drug candidates and cell death mechanisms were validated in vivo in zebrafish embryos. Full integration with the LOGGIC Core study was ensured by material and data exchanged, to deliver novel treatment approaches for the treatment of pLGG. These results will result in new early phase clinical trials for pLGG patients.